Global Information
회사소개 | 문의

중국의 에녹사파린나트륨(Enoxaparin Sodium) 시장

Investigation Report on Chinese Enoxaparin Sodium Market, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 07월 상품 코드 296865
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,483,300 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,725,000 Printable & Editable PDF (Enterprisewide License)


중국의 에녹사파린나트륨(Enoxaparin Sodium) 시장 Investigation Report on Chinese Enoxaparin Sodium Market, 2018-2022
발행일 : 2018년 07월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

혈전증은 혈관내에 혈전이 형성되어 순환계를 통과하는 혈류를 방해합니다. 세계에서는 매년 1,200만명이 뇌혈전증, 뇌경색, 심근경색, 관동맥질환으로 사망하고 있습니다. 중국에서는 심혈관질환 발생률이 계속 증가하고 있습니다. 현재 심혈관질환 환자수는 성인 10명 중 2명, 약 2억 9,000만명에 이르는 것으로 추정됩니다. 에녹사파린나트륨은 Aventis(후에 Sanofi와 합병)에서 개발한 저분자량 헤파린입니다.

중국의 에녹사파린나트륨(Enoxaparin Sodium) 시장에 대해 조사 분석하고, 혈전증 발생률, 주요 제조업체의 시장 점유율, 병원 시장에서의 판매 가격, 제네릭 의약품 생산 상황, 주요 제조업체 개요, 시장 전망 등의 정보를 전해드립니다.

제1장 에녹사파린나트륨 관련 개념

  • 적응과 개발 과정
  • 세계 시장의 판매 상황
  • 주요 제조업체

제2장 중국의 에녹사파린나트륨 시장 개요

  • 특허 상황
  • 제네릭 의약품 생산 상황
  • 주요 제조업체
  • 시장 규모

제3장 중국의 에녹사파린나트륨 매출 분석

  • 총매출
  • 매출 : 지역별

제4장 중국 에녹사파린나트륨 주요 제조업체의 시장 점유율 분석

  • 시장 점유율 : 매출별
  • 시장 점유율 : 판매량별

제5장 중국의 에녹사파린나트륨(제형별) 시장 규모 분석

  • 시장 점유율 : 매출 및 제형별
  • 시장 점유율 : 판매량 및 제형별

제6장 중국 병원 시장에서의 에녹사파린나트륨 기준 가격(기업별)

  • Sanofi
  • Sanofi Winthrop Industrie S.A.
  • Hangzhou Sanofi-Aventis Minsheng Pharmaceutical Co., Ltd.
  • Hangzhou Jiuyuan Gene Engineering Co., Ltd.

제7장 중국의 에녹사파린나트륨 주요 제조업체 분석

  • Sanofi
  • Sanofi Winthrop Industrie S.A.
  • Hangzhou Sanofi-Aventis Minsheng Pharmaceutical Co., Ltd.
  • Hangzhou Jiuyuan Gene Engineering Co., Ltd.

제8장 중국의 에녹사파린나트륨 시장 전망

  • 중국의 혈전증 발생률 예측
  • 제네릭 의약품 연구 상황
  • 시장 규모 예측
  • 시장 경쟁 예측

도표

LSH 14.03.13

영문목차

Description

Heparin drugs are widely used in hemodialysis and various surgical operations. Compared with unfractionated heparin, low-molecular-weight heparin has the following advantages: no need to monitor thrombin time; smaller potential bleeding risk; smaller osteoporosis risk after long-term use; smaller risk of inducing thrombopenia.

Low-molecular-weight heparin preparations are gradually replacing unfractionated heparin preparations because of wider clinical applications. The main product of low-molecular-weight heparin preparations is Enoxaparin Sodium which was originally developed by Aventis (merged with Sanofi later) and approved to be sold in the trade name of Lovenox in 1993. Sanofi's Enoxaparin Sodium Injection was approved by FDA in Oct. 2004, and entered the Chinese market in the beginning of 2005 with a continuous growth in market size. Its sales value exceeded CNY 300 million in 2017.

Enoxaparin Sodium can be used to prevent deep vein thrombosis and pulmonary embolism, to treat established venous thrombosis, to prevent thrombus formation in extracorporeal circulation during hemodialysis, and to treat unstable angina and non-Q-wave myocardial infarction.

According to CRI, generic drugs also takes up some market share because the average price of Sanofi's products is comparatively high. Many pharmaceutical enterprises in China have obtained the production permit for Enoxaparin Sodium injection. CRI's market research shows that the Chinese market is dominated by Sanofi. Other major market players include Hangzhou Jiuyuan Gene Engineering Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., etc. In 2017, the top 5 manufacturers took up over 90% market share by sales value, with Sanofi's market share reaching approximately 80%. Sanofi's market share is gradually flowing to domestic enterprises because of high average price. It is estimated that Sanofi will have ever smaller market share in the coming years with more Enoxaparin Sodium manufacturers entering the market in China.

According to CRI, as China's population ages, the incidence of vascular embolic disease continues to rise. At the same time, as the incidence of ESRD in China continues to rise, the number of people receiving hemodialysis is also rising. All these factors have driven the growth of the Enoxaparin Sodium market. There is still a large growth potential for the Chinese Enoxaparin Sodium market.

Topics Covered:

  • Incidence of thrombosis in China
  • Development history of Enoxaparin Sodium in China
  • Sales of Enoxaparin Sodium in China
  • Prices of Enoxaparin Sodium in China
  • Major Enoxaparin Sodium manufacturers in China
  • Prospects of Chinese Enoxaparin Sodium Market

Table of Contents

Table of Contents

1 Relevant Concepts of Enoxaparin Sodium

  • 1.1 Indications for Enoxaparin Sodium
  • 1.2 Development History of Enoxaparin Sodium in China
  • 1.3 Production Permit of Enoxaparin Sodium in China

2 Analysis on Sales of Enoxaparin Sodium in China, 2013-2017

  • 2.1 Sales Value of Enoxaparin Sodium
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value in Key Regions of China
  • 2.2 Sales Volume of Enoxaparin Sodium
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume in Key Regions of China
  • 2.3 Sales of Enoxaparin Sodium in Different Dosage Forms in China

3 Major Enoxaparin Sodium Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Shares of Major Enoxaparin Sodium Manufacturers in China
    • 3.1.1 Market Shares by Sales Value
    • 3.1.2 Market Shares by Sales Volume
  • 3.2 Sanofi
    • 3.2.1 Profile of Sanofi
    • 3.2.2 Sales of Sanofi's Enoxaparin Sodium in China

(The structures of 3.3-3.6 are similar with that of 3.2.)

  • 3.3 Hangzhou Jiuyuan Gene Engineering Co., Ltd.
  • 3.4 Shenzhen Techdow Pharmaceutical Co., Ltd.
  • 3.5 Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
  • 3.6 Chengdu Baiyu Pharmaceutical Co., Ltd.
  • 3.7 Suzhou Erye Pharmaceutical Co., Ltd.
  • 3.8 Beijing SL Pharmaceutical Co., Ltd.
  • 3.9 Changzhou Qianhong Bio-pharma Co., Ltd.

4 Prices of Enoxaparin Sodium in China, 2017-2018

  • 4.1 Analysis on Average Price of Enoxaparin Sodium in China
  • 4.2 Analysis on Prices of Enoxaparin Sodium in Different Regions of China
  • 4.3 Analysis on Prices of Enoxaparin Sodium of Different Enterprises in China
    • 4.3.1 Sanofi
    • 4.3.2 Hangzhou Jiuyuan Gene Engineering Co., Ltd.
    • 4.3.3 Shenzhen Techdow Pharmaceutical Co., Ltd.
    • 4.3.4 Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
    • 4.3.5 Chengdu Baiyu Pharmaceutical Co., Ltd.
    • 4.3.6 Suzhou Erye Pharmaceutical Co., Ltd.
    • 4.3.7 Beijing SL Pharmaceutical Co., Ltd.
    • 4.3.8 Changzhou Qianhong Bio-pharma Co., Ltd.

5 Prospects of Chinese Enoxaparin Sodium Market, 2018-2022

  • 5.1 Forecast on Incidence of Indications in China
  • 5.2 Forecast on Size of Enoxaparin Sodium Market
  • 5.3 Forecast on Trend of Enoxaparin Sodium Market

Selected Charts

  • Chart Enoxaparin Sodium Products Approved to Market in China by 2018
  • Chart Sales Value of Enoxaparin Sodium in China, 2013-2017
  • Chart Sales Value of Enoxaparin Sodium by Region in China, 2013-2017
  • Chart Market Shares of Major Enoxaparin Sodium Manufacturers in China (by Sales Value)
  • Chart Price of Sanofi's Enoxaparin Sodium in China, 2017-2018
  • Chart Profile of Hangzhou Jiuyuan Gene Engineering Co., Ltd.
  • Chart Sales of Hangzhou Jiuyuan Gene Engineering Co., Ltd.'s Enoxaparin Sodium, 2013-2017
  • Chart Price of Hangzhou Jiuyuan Gene Engineering Co., Ltd.'s Enoxaparin Sodium in China, 2017-2018
  • Chart Forecast on Size of Chinese Enoxaparin Sodium Market, 2018-2022
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research